We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Tumour network in the brain increases treatment resistance
News

Tumour network in the brain increases treatment resistance

Tumour network in the brain increases treatment resistance
News

Tumour network in the brain increases treatment resistance

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Tumour network in the brain increases treatment resistance"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Astrocytomas are a special type of brain tumor that are difficult to treat as they do not respond to standard forms of treatment. One reason for this resistance could be their ability to form a communication network. This was discovered by scientists taking part in an international study involving experts from the Comprehensive Cancer Center (CCC) of the Medical University (MedUni) of Vienna and Vienna General Hospital. The study is published in the journal Nature and is regarded as a milestone.


Gliomas are tumors of the central nervous system and are subdivided into astrocytomas and oligodendrogliomas. Whilst oligodendrogliomas are relatively rare, with only 40 new cases every year, and respond well to standard radiotherapy and chemotherapy treatments, astrocytomas are highly invasive and difficult to treat. For this reason they are also associated with a poor prognosis: sufferers usually only survive for a few years. In Austria around 400 people develop an astrocytoma every year.


Until now it has not been understood why astrocytomas respond so poorly to current treatments compared with other gliomas. In the present study, which was set up in collaboration with the University of Heidelberg, the study team successfully identified a starting point that opens up the possibility of treating astrocytomas more effectively in future. Matthias Preusser, specialist in brain tumors at the University Department of Internal Medicine I at MedUni Vienna and Vienna General Hospital, head of the CCC unit for tumors of the central nervous system (CCC-CNS) and co-author of the new study, in which the Clinical Institute for Neurology of MedUni Vienna and Vienna General Hospital also took part, says: "Astrocytomas form interconnecting communication networks. To do this, the tumor cells form long thin channels from their membranes, so-called tumor microtubules, that connect them to other tumor cells. They use these channels to exchange information and molecules in the form of electrical charges and calcium. This network favors the spread of tumor cells, cell division and makes astrocytomas more resistant to treatment." Indeed, using this network, astrocytomas are able to initiate repair mechanisms and so eliminate any damage to individual tumor cells caused, for example, by radiotherapy treatment.


New therapeutic approach: disrupting the network

One approach to achieving more therapeutic success in the future is to disrupt communication between the astrocytomas by blocking the channel system. Preusser: "It is conceivable that greater therapeutic success could be achieved by using drugs to disrupt the formation or function of the membrane channels." The research team was able to show that the network interfaces are created by a certain molecule, connexin 43, that is able to form pores. On the other hand, the protein GAP 43 seems to play an important role in the formation of the microtubules. Preusser: "Potential treatment strategies could therefore be to chemically inhibit the tumour cell network using calcium blockers or substances that affect connexin 43 or GAP 43."


Note: Material may have been edited for length and content. For further information, please contact the cited source.

Medical University of Vienna   press release


Publication

Osswald M et al. Brain tumour cells interconnect to a functional and resistant network.   Nature, Published Online November 4 2015. doi: 10.1038/nature16071


Advertisement